Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of the intrahepatic bile ducts. Currently, the first line drug for PBC is ursodeoxycholic acid (UDCA) characterized by anti-apoptotic, anti-inflammatory and protective actions on chol...
Main Authors: | Ludovico Abenavoli, Anna Caterina Procopio, Sharmila Fagoonee, Rinaldo Pellicano, Marco Carbone, Francesco Luzza, Pietro Invernizzi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Diseases |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-9721/8/2/20 |
Similar Items
-
Update on Emerging Treatment Options for Primary Biliary Cholangitis
by: Aguilar MT, et al.
Published: (2020-05-01) -
Primary biliary cholangitis
by: I. M. Iljinsky, et al.
Published: (2021-04-01) -
New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
by: Jhaveri MA, et al.
Published: (2017-08-01) -
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
by: Cynthia Levy
Published: (2017-09-01) -
On the Pharmacology of Farnesoid X Receptor Agonists: Give me an “A”, Like in “Acid”
by: Eva Hambruch, et al.
Published: (2016-06-01)